Duchenne Muscular Dystrophy - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：199頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Duchenne Muscular Dystrophy - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Duchenne Muscular Dystrophy - Pipeline Review, H1 2014’, provides an overview of the Duchenne Muscular Dystrophy’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Duchenne Muscular Dystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Duchenne Muscular Dystrophy and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Duchenne Muscular Dystrophy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Duchenne Muscular Dystrophy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Duchenne Muscular Dystrophy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Duchenne Muscular Dystrophy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Duchenne Muscular Dystrophy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Duchenne Muscular Dystrophy - Pipeline Review, H1 2014’, provides an overview of the Duchenne Muscular Dystrophy’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Duchenne Muscular Dystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Duchenne Muscular Dystrophy and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Duchenne Muscular Dystrophy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Duchenne Muscular Dystrophy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Duchenne Muscular Dystrophy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Duchenne Muscular Dystrophy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Duchenne Muscular Dystrophy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Duchenne Muscular Dystrophy Overview 8
Therapeutics Development 9
Pipeline Products for Duchenne Muscular Dystrophy - Overview 9
Pipeline Products for Duchenne Muscular Dystrophy - Comparative Analysis 10
Duchenne Muscular Dystrophy - Therapeutics under Development by Companies 11
Duchenne Muscular Dystrophy - Therapeutics under Investigation by Universities/Institutes 15
Duchenne Muscular Dystrophy - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Duchenne Muscular Dystrophy - Products under Development by Companies 20
Duchenne Muscular Dystrophy - Products under Investigation by Universities/Institutes 23
Duchenne Muscular Dystrophy - Companies Involved in Therapeutics Development 24
Sanofi 24
Eli Lilly and Company 25
Daiichi Sankyo Company, Limited 26
Nippon Shinyaku Co., Ltd. 27
Sarepta Therapeutics, Inc. 28
NicOx S.A. 29
Galapagos NV 30
Summit Corporation plc 31
Santhera Pharmaceuticals Holding AG 32
Shenzhen Beike Biotechnology Co., Ltd. 33
Italfarmaco S.p.A. 34
Prosensa Holding BV 35
Catabasis Pharmaceuticals, Inc. 36
Nobelpharma Co., Ltd. 37
PTC Therapeutics, Inc. 38
Fate Therapeutics, Inc. 39
N-Gene Research Laboratories, Inc. 40
Asklepios BioPharmaceutical, Inc. 41
Genethon 42
miRagen Therapeutics, Inc. 43
Prosensa Therapeutics B.V. 44
EryDel SPA 45
Myomics, Inc. 46
Prothelia, Inc. 47
ReveraGen BioPharma, Inc. 48
Retrophin, LLC 49
Duchenne Muscular Dystrophy - Therapeutics Assessment 50
Assessment by Monotherapy Products 50
Assessment by Combination Products 51
Assessment by Target 52
Assessment by Mechanism of Action 55
Assessment by Route of Administration 58
Assessment by Molecule Type 61
Drug Profiles 64
ataluren - Drug Profile 64
ataluren - Drug Profile 67
drisapersen - Drug Profile 70
tadalafil - Drug Profile 72
idebenone - Drug Profile 74
Epigallocatechin Gallate - Drug Profile 77
eteplirsen - Drug Profile 79
PRO-045 - Drug Profile 81
CRD-007 - Drug Profile 83
poloxamer - Drug Profile 84
NPC-14 - Drug Profile 85
PRO-044 - Drug Profile 86
givinostat - Drug Profile 88
PRO-053 - Drug Profile 90
NU-211-01 + NU-215-02 - Drug Profile 92
AAV1-FS-344 - Drug Profile 93
SMTC-1100 - Drug Profile 94
Biostrophin - Drug Profile 96
dexamethasone - Drug Profile 97
CAT-1004 - Drug Profile 99
HLA-Identical Allogeneic Mesoangioblasts - Drug Profile 101
NS-065 - Drug Profile 102
SRP-4050 - Drug Profile 103
naproxcinod - Drug Profile 104
GLPG-0492 - Drug Profile 106
BGP-15 - Drug Profile 107
MGN-8107 - Drug Profile 109
PRO-052 - Drug Profile 110
PRO-055 - Drug Profile 111
FT-301 - Drug Profile 112
Drug For Duchenne Muscular Dystrophy - Drug Profile 114
Drug For Duchenne Muscular Dystrophy - Drug Profile 115
PRT-01 - Drug Profile 116
PRT-20 - Drug Profile 118
VBP-15 - Drug Profile 119
RE-001 - Drug Profile 121
CAT-1040 - Drug Profile 122
poloxamer - Drug Profile 123
Wnt7a--Based Protein Thearpeutics - Drug Profile 124
RTC-13 - Drug Profile 126
SRP-4045 - Drug Profile 128
RTC-14 - Drug Profile 129
AAV5 Gene Therapy - Drug Profile 130
Drug Targeting Utrophin - Drug Profile 131
SRP-4053 - Drug Profile 132
ARM-210 - Drug Profile 133
Recombinant Protein for Muscular Dystrophy - Drug Profile 134
tamoxifen citrate - Drug Profile 135
Gene Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile 136
GsMTx-4 - Drug Profile 137
L-379 - Drug Profile 139
Muscle Targeting Peptides - Drug Profile 140
PROSPECT - Drug Profile 141
CAT-1041 - Drug Profile 142
MG-53 - Drug Profile 143
NBD peptide - Drug Profile 145
PRT-300 - Drug Profile 146
PRT-400 - Drug Profile 147
PRT-500 - Drug Profile 148
ENA oligonucleotide - Drug Profile 149
Drug Targeting Serca2a - Drug Profile 150
Small Molecules to Modulate Utrophin for Duchenne Muscular Dystrophy - Drug Profile 151
Small Molecule for Duchenne Muscular Dystrophy - Drug Profile 152
Duchenne Muscular Dystrophy - Recent Pipeline Updates 153
Duchenne Muscular Dystrophy - Dormant Projects 182
Duchenne Muscular Dystrophy - Discontinued Products 183
Duchenne Muscular Dystrophy - Product Development Milestones 184
Featured News & Press Releases 184
Appendix 193
Methodology 193
Coverage 193
Secondary Research 193
Primary Research 193
Expert Panel Validation 193
Contact Us 194
Disclaimer 194
List of Tables
Number of Products under Development for Duchenne Muscular Dystrophy, H1 2014 14
Number of Products under Development for Duchenne Muscular Dystrophy - Comparative Analysis, H1 2014 15
Number of Products under Development by Companies, H1 2014 17
Number of Products under Development by Companies, H1 2014 (Contd..1) 18
Number of Products under Development by Companies, H1 2014 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H1 2014 21
Comparative Analysis by Late Stage Development, H1 2014 22
Comparative Analysis by Clinical Stage Development, H1 2014 23
Comparative Analysis by Early Stage Development, H1 2014 24
Products under Development by Companies, H1 2014 25
Products under Development by Companies, H1 2014 (Contd..1) 26
Products under Development by Companies, H1 2014 (Contd..2) 27
Products under Investigation by Universities/Institutes, H1 2014 28
Duchenne Muscular Dystrophy - Pipeline by Sanofi, H1 2014 29
Duchenne Muscular Dystrophy - Pipeline by Eli Lilly and Company, H1 2014 30
Duchenne Muscular Dystrophy - Pipeline by Daiichi Sankyo Company, Limited, H1 2014 31
Duchenne Muscular Dystrophy - Pipeline by Nippon Shinyaku Co., Ltd., H1 2014 32
Duchenne Muscular Dystrophy - Pipeline by Sarepta Therapeutics, Inc., H1 2014 33
Duchenne Muscular Dystrophy - Pipeline by NicOx S.A., H1 2014 34
Duchenne Muscular Dystrophy - Pipeline by Galapagos NV, H1 2014 35
Duchenne Muscular Dystrophy - Pipeline by Summit Corporation plc, H1 2014 36
Duchenne Muscular Dystrophy - Pipeline by Santhera Pharmaceuticals Holding AG, H1 2014 37
Duchenne Muscular Dystrophy - Pipeline by Shenzhen Beike Biotechnology Co., Ltd., H1 2014 38
Duchenne Muscular Dystrophy - Pipeline by Italfarmaco S.p.A., H1 2014 39
Duchenne Muscular Dystrophy - Pipeline by Prosensa Holding BV, H1 2014 40
Duchenne Muscular Dystrophy - Pipeline by Catabasis Pharmaceuticals, Inc., H1 2014 41
Duchenne Muscular Dystrophy - Pipeline by Nobelpharma Co., Ltd., H1 2014 42
Duchenne Muscular Dystrophy - Pipeline by PTC Therapeutics, Inc., H1 2014 43
Duchenne Muscular Dystrophy - Pipeline by Fate Therapeutics, Inc., H1 2014 44
Duchenne Muscular Dystrophy - Pipeline by N-Gene Research Laboratories, Inc., H1 2014 45
Duchenne Muscular Dystrophy - Pipeline by Asklepios BioPharmaceutical, Inc., H1 2014 46
Duchenne Muscular Dystrophy - Pipeline by Genethon, H1 2014 47
Duchenne Muscular Dystrophy - Pipeline by miRagen Therapeutics, Inc., H1 2014 48
Duchenne Muscular Dystrophy - Pipeline by Prosensa Therapeutics B.V., H1 2014 49
Duchenne Muscular Dystrophy - Pipeline by EryDel SPA, H1 2014 50
Duchenne Muscular Dystrophy - Pipeline by Myomics, Inc., H1 2014 51
Duchenne Muscular Dystrophy - Pipeline by Prothelia, Inc., H1 2014 52
Duchenne Muscular Dystrophy - Pipeline by ReveraGen BioPharma, Inc., H1 2014 53
Duchenne Muscular Dystrophy - Pipeline by Retrophin, LLC, H1 2014 54
Assessment by Monotherapy Products, H1 2014 55
Assessment by Combination Products, H1 2014 56
Number of Products by Stage and Target, H1 2014 59
Number of Products by Stage and Mechanism of Action, H1 2014 62
Number of Products by Stage and Route of Administration, H1 2014 65
Number of Products by Stage and Molecule Type, H1 2014 68
Duchenne Muscular Dystrophy Therapeutics - Recent Pipeline Updates, H1 2014 158
Duchenne Muscular Dystrophy - Dormant Projects, H1 2014 187
Duchenne Muscular Dystrophy - Discontinued Products, H1 2014 188
List of Figures
Number of Products under Development for Duchenne Muscular Dystrophy, H1 2014 14
Number of Products under Development for Duchenne Muscular Dystrophy - Comparative Analysis, H1 2014 15
Number of Products under Development by Companies, H1 2014 16
Number of Products under Investigation by Universities/Institutes, H1 2014 20
Comparative Analysis by Late Stage Development, H1 2014 22
Comparative Analysis by Clinical Stage Development, H1 2014 23
Comparative Analysis by Early Stage Products, H1 2014 24
Assessment by Monotherapy Products, H1 2014 55
Number of Products by Top 10 Target, H1 2014 57
Number of Products by Stage and Top 10 Target, H1 2014 58
Number of Products by Top 10 Mechanism of Action, H1 2014 60
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 61
Number of Products by Top 10 Route of Administration, H1 2014 63
Number of Products by Stage and Top 10 Route of Administration, H1 2014 64
Number of Products by Top 10 Molecule Type, H1 2014 66
Number of Products by Stage and Top 10 Molecule Type, H1 2014 67
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Duchenne Muscular Dystrophy Overview 8
Therapeutics Development 9
Pipeline Products for Duchenne Muscular Dystrophy - Overview 9
Pipeline Products for Duchenne Muscular Dystrophy - Comparative Analysis 10
Duchenne Muscular Dystrophy - Therapeutics under Development by Companies 11
Duchenne Muscular Dystrophy - Therapeutics under Investigation by Universities/Institutes 15
Duchenne Muscular Dystrophy - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Duchenne Muscular Dystrophy - Products under Development by Companies 20
Duchenne Muscular Dystrophy - Products under Investigation by Universities/Institutes 23
Duchenne Muscular Dystrophy - Companies Involved in Therapeutics Development 24
Sanofi 24
Eli Lilly and Company 25
Daiichi Sankyo Company, Limited 26
Nippon Shinyaku Co., Ltd. 27
Sarepta Therapeutics, Inc. 28
NicOx S.A. 29
Galapagos NV 30
Summit Corporation plc 31
Santhera Pharmaceuticals Holding AG 32
Shenzhen Beike Biotechnology Co., Ltd. 33
Italfarmaco S.p.A. 34
Prosensa Holding BV 35
Catabasis Pharmaceuticals, Inc. 36
Nobelpharma Co., Ltd. 37
PTC Therapeutics, Inc. 38
Fate Therapeutics, Inc. 39
N-Gene Research Laboratories, Inc. 40
Asklepios BioPharmaceutical, Inc. 41
Genethon 42
miRagen Therapeutics, Inc. 43
Prosensa Therapeutics B.V. 44
EryDel SPA 45
Myomics, Inc. 46
Prothelia, Inc. 47
ReveraGen BioPharma, Inc. 48
Retrophin, LLC 49
Duchenne Muscular Dystrophy - Therapeutics Assessment 50
Assessment by Monotherapy Products 50
Assessment by Combination Products 51
Assessment by Target 52
Assessment by Mechanism of Action 55
Assessment by Route of Administration 58
Assessment by Molecule Type 61
Drug Profiles 64
ataluren - Drug Profile 64
ataluren - Drug Profile 67
drisapersen - Drug Profile 70
tadalafil - Drug Profile 72
idebenone - Drug Profile 74
Epigallocatechin Gallate - Drug Profile 77
eteplirsen - Drug Profile 79
PRO-045 - Drug Profile 81
CRD-007 - Drug Profile 83
poloxamer - Drug Profile 84
NPC-14 - Drug Profile 85
PRO-044 - Drug Profile 86
givinostat - Drug Profile 88
PRO-053 - Drug Profile 90
NU-211-01 + NU-215-02 - Drug Profile 92
AAV1-FS-344 - Drug Profile 93
SMTC-1100 - Drug Profile 94
Biostrophin - Drug Profile 96
dexamethasone - Drug Profile 97
CAT-1004 - Drug Profile 99
HLA-Identical Allogeneic Mesoangioblasts - Drug Profile 101
NS-065 - Drug Profile 102
SRP-4050 - Drug Profile 103
naproxcinod - Drug Profile 104
GLPG-0492 - Drug Profile 106
BGP-15 - Drug Profile 107
MGN-8107 - Drug Profile 109
PRO-052 - Drug Profile 110
PRO-055 - Drug Profile 111
FT-301 - Drug Profile 112
Drug For Duchenne Muscular Dystrophy - Drug Profile 114
Drug For Duchenne Muscular Dystrophy - Drug Profile 115
PRT-01 - Drug Profile 116
PRT-20 - Drug Profile 118
VBP-15 - Drug Profile 119
RE-001 - Drug Profile 121
CAT-1040 - Drug Profile 122
poloxamer - Drug Profile 123
Wnt7a--Based Protein Thearpeutics - Drug Profile 124
RTC-13 - Drug Profile 126
SRP-4045 - Drug Profile 128
RTC-14 - Drug Profile 129
AAV5 Gene Therapy - Drug Profile 130
Drug Targeting Utrophin - Drug Profile 131
SRP-4053 - Drug Profile 132
ARM-210 - Drug Profile 133
Recombinant Protein for Muscular Dystrophy - Drug Profile 134
tamoxifen citrate - Drug Profile 135
Gene Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile 136
GsMTx-4 - Drug Profile 137
L-379 - Drug Profile 139
Muscle Targeting Peptides - Drug Profile 140
PROSPECT - Drug Profile 141
CAT-1041 - Drug Profile 142
MG-53 - Drug Profile 143
NBD peptide - Drug Profile 145
PRT-300 - Drug Profile 146
PRT-400 - Drug Profile 147
PRT-500 - Drug Profile 148
ENA oligonucleotide - Drug Profile 149
Drug Targeting Serca2a - Drug Profile 150
Small Molecules to Modulate Utrophin for Duchenne Muscular Dystrophy - Drug Profile 151
Small Molecule for Duchenne Muscular Dystrophy - Drug Profile 152
Duchenne Muscular Dystrophy - Recent Pipeline Updates 153
Duchenne Muscular Dystrophy - Dormant Projects 182
Duchenne Muscular Dystrophy - Discontinued Products 183
Duchenne Muscular Dystrophy - Product Development Milestones 184
Featured News & Press Releases 184
Appendix 193
Methodology 193
Coverage 193
Secondary Research 193
Primary Research 193
Expert Panel Validation 193
Contact Us 194
Disclaimer 194
List of Tables
Number of Products under Development for Duchenne Muscular Dystrophy, H1 2014 14
Number of Products under Development for Duchenne Muscular Dystrophy - Comparative Analysis, H1 2014 15
Number of Products under Development by Companies, H1 2014 17
Number of Products under Development by Companies, H1 2014 (Contd..1) 18
Number of Products under Development by Companies, H1 2014 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H1 2014 21
Comparative Analysis by Late Stage Development, H1 2014 22
Comparative Analysis by Clinical Stage Development, H1 2014 23
Comparative Analysis by Early Stage Development, H1 2014 24
Products under Development by Companies, H1 2014 25
Products under Development by Companies, H1 2014 (Contd..1) 26
Products under Development by Companies, H1 2014 (Contd..2) 27
Products under Investigation by Universities/Institutes, H1 2014 28
Duchenne Muscular Dystrophy - Pipeline by Sanofi, H1 2014 29
Duchenne Muscular Dystrophy - Pipeline by Eli Lilly and Company, H1 2014 30
Duchenne Muscular Dystrophy - Pipeline by Daiichi Sankyo Company, Limited, H1 2014 31
Duchenne Muscular Dystrophy - Pipeline by Nippon Shinyaku Co., Ltd., H1 2014 32
Duchenne Muscular Dystrophy - Pipeline by Sarepta Therapeutics, Inc., H1 2014 33
Duchenne Muscular Dystrophy - Pipeline by NicOx S.A., H1 2014 34
Duchenne Muscular Dystrophy - Pipeline by Galapagos NV, H1 2014 35
Duchenne Muscular Dystrophy - Pipeline by Summit Corporation plc, H1 2014 36
Duchenne Muscular Dystrophy - Pipeline by Santhera Pharmaceuticals Holding AG, H1 2014 37
Duchenne Muscular Dystrophy - Pipeline by Shenzhen Beike Biotechnology Co., Ltd., H1 2014 38
Duchenne Muscular Dystrophy - Pipeline by Italfarmaco S.p.A., H1 2014 39
Duchenne Muscular Dystrophy - Pipeline by Prosensa Holding BV, H1 2014 40
Duchenne Muscular Dystrophy - Pipeline by Catabasis Pharmaceuticals, Inc., H1 2014 41
Duchenne Muscular Dystrophy - Pipeline by Nobelpharma Co., Ltd., H1 2014 42
Duchenne Muscular Dystrophy - Pipeline by PTC Therapeutics, Inc., H1 2014 43
Duchenne Muscular Dystrophy - Pipeline by Fate Therapeutics, Inc., H1 2014 44
Duchenne Muscular Dystrophy - Pipeline by N-Gene Research Laboratories, Inc., H1 2014 45
Duchenne Muscular Dystrophy - Pipeline by Asklepios BioPharmaceutical, Inc., H1 2014 46
Duchenne Muscular Dystrophy - Pipeline by Genethon, H1 2014 47
Duchenne Muscular Dystrophy - Pipeline by miRagen Therapeutics, Inc., H1 2014 48
Duchenne Muscular Dystrophy - Pipeline by Prosensa Therapeutics B.V., H1 2014 49
Duchenne Muscular Dystrophy - Pipeline by EryDel SPA, H1 2014 50
Duchenne Muscular Dystrophy - Pipeline by Myomics, Inc., H1 2014 51
Duchenne Muscular Dystrophy - Pipeline by Prothelia, Inc., H1 2014 52
Duchenne Muscular Dystrophy - Pipeline by ReveraGen BioPharma, Inc., H1 2014 53
Duchenne Muscular Dystrophy - Pipeline by Retrophin, LLC, H1 2014 54
Assessment by Monotherapy Products, H1 2014 55
Assessment by Combination Products, H1 2014 56
Number of Products by Stage and Target, H1 2014 59
Number of Products by Stage and Mechanism of Action, H1 2014 62
Number of Products by Stage and Route of Administration, H1 2014 65
Number of Products by Stage and Molecule Type, H1 2014 68
Duchenne Muscular Dystrophy Therapeutics - Recent Pipeline Updates, H1 2014 158
Duchenne Muscular Dystrophy - Dormant Projects, H1 2014 187
Duchenne Muscular Dystrophy - Discontinued Products, H1 2014 188
List of Figures
Number of Products under Development for Duchenne Muscular Dystrophy, H1 2014 14
Number of Products under Development for Duchenne Muscular Dystrophy - Comparative Analysis, H1 2014 15
Number of Products under Development by Companies, H1 2014 16
Number of Products under Investigation by Universities/Institutes, H1 2014 20
Comparative Analysis by Late Stage Development, H1 2014 22
Comparative Analysis by Clinical Stage Development, H1 2014 23
Comparative Analysis by Early Stage Products, H1 2014 24
Assessment by Monotherapy Products, H1 2014 55
Number of Products by Top 10 Target, H1 2014 57
Number of Products by Stage and Top 10 Target, H1 2014 58
Number of Products by Top 10 Mechanism of Action, H1 2014 60
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 61
Number of Products by Top 10 Route of Administration, H1 2014 63
Number of Products by Stage and Top 10 Route of Administration, H1 2014 64
Number of Products by Top 10 Molecule Type, H1 2014 66
Number of Products by Stage and Top 10 Molecule Type, H1 2014 67
